Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

(2012) Sarah B. Fisher et al.   CANCER

An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma

(2012) Sarah B. Fisher et al.   CANCER

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

(2012) Yung-Jue Bang et al.   LANCET

Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer

(2012) Amir Sonnenblick et al.   MEDICAL ONCOLOGY

Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection

(2011) Shishir K. Maithel et al.   ANNALS OF SURGICAL ONCOLOGY

Preliminary indication of survival benefit fromERCC1andRRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis

(2011) George R. Simon et al.   CANCER

Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer

(2011) Jenny Andrews et al.   CANCER JOURNAL

Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

(2011) Jeeyun Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases

(2011) Shishir K. Maithel et al.   SURGERY

Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase π for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer

(2010) Sung-Hyun Kim et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy

(2010) Ki Han Kim et al.   BIOMARKERS

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy

(2010) K R Fareed et al.   BRITISH JOURNAL OF CANCER

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

(2009) J-S Kim et al.   BRITISH JOURNAL OF CANCER

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer

(2009) Wasaburo Koizumi et al.   INTERNATIONAL JOURNAL OF CANCER

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

(2008) J Matsubara et al.   BRITISH JOURNAL OF CANCER

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH